局限期弥漫大B细胞淋巴瘤的当前管理与挑战
近期研究关注低危患者缩短化疗和省略放疗的安全性及PET引导的反应适应策略,但证据限于年轻无危险因素患者,老年或高危患者应用受限。现代放疗毒性低,即使低危患者也不能排除放疗的临床获益,需多学科个体化风险获益评估。
要点
- 低危年轻患者可考虑缩短化疗和省略放疗,但老年或高危患者证据不足。
- 放疗在特定情境仍有用,现代技术毒性低,应个体化多学科评估。
核心结论
- 局限期DLBCL预后总体良好,治疗需平衡疾病控制与长期毒性。
- 低危患者省略放疗的趋势需谨慎,现有证据不能排除放疗的临床获益。
- 结外局限期DLBCL(约40%)的最佳方案因原发部位而异。
研究设计与样本
- 综述,总结最新临床试验证据并讨论常规实践应用。
主要发现
- 4–6周期R-CHOP alone或3–4周期联合受累部位放疗预后良好。
- 近期研究聚焦低危患者缩短化疗和省略放疗的安全性及PET反应适应策略。
- 研究限于年轻无危险因素患者,老年或高危患者应用受限。
- 结外局限期DLBCL约占40%,最佳方案因原发部位而异。
关键数值与推荐
- 局限期DLBCL可采用4–6周期R-CHOP alone或3–4周期联合受累部位放疗。
- 低危患者可考虑缩短化疗和省略放疗,但需个体化风险获益评估。
- 现代放疗技术毒性低,特定情境下放疗仍是有用辅助手段。
临床怎么用
- 低危年轻局限期患者可考虑缩短化疗和省略放疗,但需多学科评估。
- 老年或高危患者因证据不足,应谨慎应用低危患者的治疗策略。
- 结外局限期DLBCL需根据原发部位制定个体化方案。
局限性
- 近期研究限于年轻无危险因素患者,老年或高危患者证据缺乏。
- 现有证据不能排除低危患者从放疗中的临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Twenty-five to thirty per cent of diffuse large B-cell lymphoma (DLBCL) presents as limited stage (I-II). Prognosis is generally excellent with four to six cycles of R-CHOP alone (rituximab, cyclophosphamide, vincristine, doxorubicin, prednisolone) or combined-modality therapy with three or four cycles and involved-site radiotherapy (RT). There is growing interest in optimising algorithms to retain disease control whilst minimising long-term toxicity, with several recent studies focusing on the safety of abbreviating chemotherapy and omitting RT in low-risk patients and the utility of PET-based response-adapted approaches. As these studies are limited to younger patients without risk factors, application of similar approaches in elderly or higher-risk patients is hampered by a lack of evidence. Whilst there has been a move away from using RT in low-risk patients, it remains a useful adjunct in specific situations. Current evidence cannot exclude a clinically meaningful benefit from RT even in low-risk patients and, given the low expected toxicity from modern RT techniques, a risk-benefit assessment should be individualised and considered in a multidisciplinary fashion. The optimal approach for extranodal limited-stage DLBCL (~40% of cases) varies according to site of origin. Herein we discuss the latest clinical trial evidence and how this can be applied in routine practice.
引用
- Zhang XY, Collins GP, Cutter DJ, et al. Limited-stage diffuse large B-cell lymphoma: current management and challenges. Br J Haematol. 2021. PMID: 33618434. doi:10.1111/bjh.17359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。